CareDx Inc (CDNA)vsWaters Corporation (WAT)
CDNA
CareDx Inc
$28.82
-3.76%
HEALTHCARE · Cap: $1.20B
WAT
Waters Corporation
$374.41
-2.95%
HEALTHCARE · Cap: $36.25B
Smart Verdict
WallStSmart Research — data-driven comparison
Waters Corporation generates 813% more annual revenue ($3.77B vs $412.82M). WAT leads profitability with a 11.9% profit margin vs -2.0%. WAT earns a higher WallStSmart Score of 50/100 (C-).
CDNA
Hold37
out of 100
Grade: F
WAT
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+57.7%
Fair Value
$46.59
Current Price
$28.82
$17.77 discount
Margin of Safety
-84.0%
Fair Value
$178.93
Current Price
$374.41
$195.48 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 39.0% year-over-year
Conservative balance sheet, low leverage
Revenue surging 91.4% year-over-year
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of 1.5%
Weak financial health signals
Expensive relative to growth rate
ROE of 2.9% — below average capital efficiency
Operating margin of 2.8%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CDNA
The strongest argument for CDNA centers on Revenue Growth, Debt/Equity. Revenue growth of 39.0% demonstrates continued momentum.
Bull Case : WAT
The strongest argument for WAT centers on Revenue Growth, Altman Z-Score, Price/Book. Revenue growth of 91.4% demonstrates continued momentum.
Bear Case : CDNA
The primary concerns for CDNA are EPS Growth, Market Cap, Operating Margin.
Bear Case : WAT
The primary concerns for WAT are PEG Ratio, Return on Equity, Operating Margin. A P/E of 47.0x leaves little room for execution misses.
Key Dynamics to Monitor
CDNA profiles as a hypergrowth stock while WAT is a growth play — different risk/reward profiles.
CDNA carries more volatility with a beta of 2.48 — expect wider price swings.
WAT is growing revenue faster at 91.4% — sustainability is the question.
CDNA generates stronger free cash flow (514,000), providing more financial flexibility.
Bottom Line
WAT scores higher overall (50/100 vs 37/100) and 91.4% revenue growth. CDNA offers better value entry with a 57.7% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CareDx Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally. The company is headquartered in South San Francisco, California.
Waters Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?